Clinical Characteristics and Outcomes of Patients Undergoing Pericardiocentesis for Pericardial Effusion: A Single-Center Experience with Exploratory Inflammatory Biomarker Analysis
- 1Department of Cardiology, Bakırçay University Çiğli Training and Research Hospital, Izmir 35620, Türkiye
- 2Department of Pathology, Bakırçay University Çiğli Training and Research Hospital, Izmir 35620, Türkiye
Abstract
Objective: We aim to characterize patients undergoing pericardiocentesis for clinically significant pericardial effusion and explore differences in inflammation-based biomarkers according to malignancy status and one-year outcome. Methods: We retrospectively evaluated 113 consecutive patients who underwent pericardiocentesis between January 2021 and January 2026. Clinical, laboratory, pericardial fluid, cytopathological, recurrence, and mortality data were analyzed. NLR, PLR, SII, SIRI, and PIV were assessed as secondary exploratory biomarkers. Results: Malignancy-associated pericardial effusion was present in 36 patients (31.9%), while 77 (68.1%) had non-malignant effusion. The malignancy-associated group had more frequent dyspnea (77.8% vs. 55.8%; p = 0.025), effusion >15 mm (80.6% vs. 58.4%; p = 0.021), hemorrhagic fluid (75.0% vs. 54.5%; p = 0.038), and recurrence (38.9% vs. 20.8%; p = 0.042). Malignant cells were identified in pericardial fluid cytology in 15/36 patients (41.7%). One-year mortality was 22.2% versus 13.0% (p = 0.211). NLR, PLR, SII, SIRI, and PIV did not differ significantly according to malignancy status or one-year mortality; NLR, PLR, and SIRI were higher in the exploratory lung cancer subgroup. Conclusions: Malignancy-associated pericardial effusion showed distinct clinical and fluid characteristics. No statistically significant associations were detected between the evaluated inflammation-based biomarkers and malignancy status or one-year mortality; however, the exploratory design and limited number of outcome events warrant cautious interpretation.
Related
- Desmoplastic Malignant Mesothelioma of the Pericardium Mimicking Inflammatory Pericardial Disease: An Autopsy Case Report
- Baseline Patient and Tumour Characteristics Associated with Mental Health in Men Undergoing Active Surveillance for Prostate Cancer
- Clinical characteristics and exploratory factors associated with in-hospital mortality in pediatric severe viral encephalitis
- Peripheral Nerve Conduction and Anthropometric Characteristics in Elite American Football Players: An Exploratory Cross-Sectional Study
- Associations Between Upright Cardiovascular-Autonomic Characteristics, Temporal Gait Measures, and Mediolateral Plantar Center-of-Force Measures in Adults with Developmental Disabilities: An Exploratory Cross-Sectional Study
BibTeX
@article{emren2026clinical,
title = {{Clinical Characteristics and Outcomes of Patients Undergoing Pericardiocentesis for Pericardial Effusion: A Single-Center Experience with Exploratory Inflammatory Biomarker Analysis}},
author = {Zeynep Yapan Emren and Gamze Erkılınç},
journal = {Journal of clinical medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15197679},
url = {https://europepmc.org/article/PMC/PMC13666445},
note = {CC BY},
}
RIS
TY - JOUR
TI - Clinical Characteristics and Outcomes of Patients Undergoing Pericardiocentesis for Pericardial Effusion: A Single-Center Experience with Exploratory Inflammatory Biomarker Analysis
AU - Zeynep Yapan Emren
AU - Gamze Erkılınç
PY - 2026
DA - 2026/10/01
JO - Journal of clinical medicine
DO - 10.3390/jcm15197679
UR - https://europepmc.org/article/PMC/PMC13666445
AB - Objective: We aim to characterize patients undergoing pericardiocentesis for clinically significant pericardial effusion and explore differences in inflammation-based biomarkers according to malignancy status and one-year outcome. Methods: We retrospectively evaluated 113 consecutive patients who underwent pericardiocentesis between January 2021 and January 2026. Clinical, laboratory, pericardial fluid, cytopathological, recurrence, and mortality data were analyzed. NLR, PLR, SII, SIRI, and PIV were assessed as secondary exploratory biomarkers. Results: Malignancy-associated pericardial effusion was present in 36 patients (31.9%), while 77 (68.1%) had non-malignant effusion. The malignancy-associated group had more frequent dyspnea (77.8% vs. 55.8%; p = 0.025), effusion >15 mm (80.6% vs. 58.4%; p = 0.021), hemorrhagic fluid (75.0% vs. 54.5%; p = 0.038), and recurrence (38.9% vs. 20.8%; p = 0.042). Malignant cells were identified in pericardial fluid cytology in 15/36 patients (41.7%). One-year mortality was 22.2% versus 13.0% (p = 0.211). NLR, PLR, SII, SIRI, and PIV did not differ significantly according to malignancy status or one-year mortality; NLR, PLR, and SIRI were higher in the exploratory lung cancer subgroup. Conclusions: Malignancy-associated pericardial effusion showed distinct clinical and fluid characteristics. No statistically significant associations were detected between the evaluated inflammation-based biomarkers and malignancy status or one-year mortality; however, the exploratory design and limited number of outcome events warrant cautious interpretation.
SN - 2077-0383
ER -